Skip to main content

Catalyst Calendar

Scope
Catalyst

Mon, Sep 14, 2026

1 updates
AZN
2:00 AM

Update on SERENA-4 Phase III trial

This announcement contains inside information 14 September 2026 Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer SERENA-4 trial did not meet primary objective of statistically significant improvement in progression-free survival, however a numerical improvement was observed...

Trial Results • Phase 3SERENA-4 trial results Mon, Sep 14, 2026, 8:00 AM CETastrazeneca.com

Tue, Sep 8, 2026

1 updates
AZN
9:00 AM

Imfinzi+Imdelltra improved OS in small cell lung

8 September 2026 Imfinzi plus Imdelltra demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer Imfinzi is the first and only immunotherapy in combination with a bispecific T-cell engager to show survival benefit in this setting...

Trial Results • Phase 3Results event Tue, Sep 8, 2026astrazeneca.com

Tue, Sep 1, 2026

1 updates
AZN
2:00 AM

Tagrisso + Orpathys improved PFS in 1L EGFRm lung

1 September 2026 Tagrisso plusOrpathysdemonstrated statistically significant and highly clinically meaningful improvement in progression-free survival in 1st-line MET-overexpressing EGFR-mutated lung cancer Results of SANOVO Phase III trial in China build on established success of global SAFFRON and China SACHI trials, extending clinical value of the...

Trial Results • Phase 3oral presentation Tue, Sep 1, 2026astrazeneca.com

Thu, Aug 27, 2026

1 updates
AZN
2:15 AM

Tezspire CROSSING trial met primary endpoints

27 August 2026 Tezspire demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints Statistically significant and clinically meaningful disease and symptom improvements compared to placebo maintained through week 52 Efficacy in a third epithelial-driven inflammatory disease supports broad...

Trial Results • Phase 3Results event Thu, Aug 27, 2026astrazeneca.com

Mon, Aug 17, 2026

3 updates
AZN
2:30 AM

Enhertu improved PFS in 1L HER2m lung cancer

17 August 2026 Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial AstraZeneca and Daiichi Sankyo's Enhertu is the first and only HER2-directed medicine to improve...

Trial Results • Phase 3Results event Mon, Aug 17, 2026astrazeneca.com
AZN
2:05 AM

Update on eVOLVE-Lung02 Phase III trial

17 August 2026 Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer AstraZeneca is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemotherapy in patients with metastatic non-small cell...

Trial Results • Phase 3IDMC trial data review and trial discontinuation Mon, Aug 17, 2026, 8:05 AM CETastrazeneca.com
AZN
2:00 AM

Tagrisso+Orpathys improved PFS & OS in EGFRm lung

17 August 2026 Tagrisso plus Orpathys demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on Tagrisso First global Phase III trial to show significant progression-free and overall survival benefits in this setting SAFFRON trial results...

Trial Results • Phase 3Results event Mon, Aug 17, 2026astrazeneca.com

Mon, Jul 27, 2026

2 updates
AZN
2:10 AM

Update on Ultomiris Phase III trial in HSCT-TMA

27 July 2026 Update on Phase III trial of Ultomiris in adults and adolescents with thrombotic microangiopathy after haematopoietic stem cell transplant High-level results from the ALXN1210-TMA-313 Phase III clinical trial showed that Ultomiris (ravulizumab) did not achieve statistical significance for the primary endpoint of event-free survival through 26...

Trial Results • Phase 3Trial results Mon, Jul 27, 2026, 8:10 AM CETastrazeneca.com
AZN
2:05 AM

Sone-Ve improved survival in gastric cancers

27 July 2026 Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers Results provide opportunity to expand CLDN18.2 positivity to ≥25% expression, representing approximately 60% of patients in this setting...

Trial Results • Phase 3Results event Mon, Jul 27, 2026astrazeneca.com

Thu, Jul 9, 2026

1 updates
AZN
2:00 AM

Update on CARDIO-TTRansform Phase III trial

[This announcement contains inside information] 9 July 2026 Update on CARDIO-TTRansform Phase III trial for Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy The CARDIO-TTRansform Phase III trial1 for AstraZeneca and Ionis' Wainua (eplontersen) in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) did not...

Trial Results • Phase 3Trial results Thu, Jul 9, 2026, 8:00 AM CETastrazeneca.com